Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
Ben R. Taylor, the President and Chief Financial Officer of Tyme
Technologies, Inc. (the Company), will present at the 6th Annual
Marcum Microcap Conference on Thursday June15, 2017 at
approximately 3:30 p.m. EDT. The slides that Mr.Taylor will
present are furnished herewith as Exhibit 99.1.
The information furnished to Item 7.01, including Exhibit 99.1,
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities under that Section and shall not be
deemed to be incorporated by reference into any filing of the
Company under the Securities Act of 1933 or the Exchange Act.
This Current Report (including the exhibit hereto) will not be
deemed an admission as to the materiality of any information
required to be disclosed solely to satisfy the requirements of
Regulation FD.
| Item9.01. | Financial Statements and Exhibits. |
Set forth below is the exhibit to this Current Report on Form
8-K.
|
Exhibit Number |
Description |
|
| 99.1 |
Slides for the presentation by Ben R. Taylor at the 6th Annual Marcum Microcap Conference on Thursday, June15, 2017 (such Exhibit 99.1 is furnished and not filed). |
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
